



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 4 October, 2022

Complying with the disclosure duties set out in article 226 of the Revised Text of the Securities Market Act, Laboratorios Farmacéuticos ROVI, S.A. (ROVI) informs the National Securities Market Commission of the following

OTHER RELEVANT INFORMATION

ROVI, Càrniques Ceirà and Grupo Costa have signed a joint venture agreement to construct a plant for the production of compounds of high technological value. It involves the creation of a national structure for self-sufficiency in heparins and products of high nutritional value to be used in the composition of animal feed and fertilisers.

The attached note contains further information on said project. A press release, which may be accessed through the Company's website, will be distributed today.

Mr Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.



Glicopepton Biotech founded to produce compounds of high technological value

- **ROVI, Càrniques Celrà and Grupo Costa announce the construction of a facility at the Industrial Logistics Platform in Fraga (Huesca) to produce compounds of high technological value.**
- **The project will entail a joint investment of approximately 40 million euros.**
- **Glicopepton Biotech bets on the creation of a national structure for self-sufficiency in heparins that will preserve Spain's pig value chain.**

Madrid – 4 October 2022 – Laboratorios Farmacéuticos ROVI, S.A. (ROVI or the "Company"), Càrniques Celrà, S.L. and Grupo Empresarial Costa, S.L. present Glicopepton Biotech, S. L., a joint venture that involves the creation of one of the first national structures for self-sufficiency in heparins and products of high nutritional value to be used in the composition of animal feed and fertilisers. The goals of this project focus on transforming the present livestock production process into a high-value-added technological process based on a circular economy model.

The project involves the construction of a facility at the Industrial Logistics Platform of Fraga (Huesca), which will produce compounds of high biological value that derive from the intestinal mucosa of pigs. It will involve a joint investment of approximately 40 million euros over the next four years and is expected to create around 30 direct skilled jobs. The project will be subject to obtaining the applicable administrative and regulatory permits and authorisations.

Glicopepton Biotech combines ROVI's experience as a leading company in the research into low-molecular-weight heparins (LMWH) with the track records of Càrniques Celrà and Grupo Empresarial Costa, two major companies in the livestock and meat industry in Spain. LMWHs are anticoagulant drugs used to prevent and treat venous thromboembolic disease.

They are a biological product whose raw material is obtained from the intestinal mucosa of pigs. This project seeks both the creation of economic and technological value, transforming pig mucosa into a high-value-added product like heparin, and the development of new animal food supplements and fertilisers.

ROVI has in-house production capacity to transform raw heparin into sodium heparin and intends to expand this capacity through the construction of a new sodium heparin production line (already underway), in order to be present in all the manufacturing phases of low-molecular-weight heparins.

Juan López-Belmonte Encina, ROVI's chairman and chief executive officer, highlighted "*the strategic importance for Spain of a project with these characteristics, since it provides the country with the capacity to be self-sufficient in obtaining a raw material that is indispensable for the production of an essential medicine like low-molecular-weight heparins. At ROVI, we are very excited about this project since, as a company specialised in these medicines, it will enable us to take a further step in the vertical integration of our LMWH manufacturing.*"

About Glicopepton Biotech

ROVI, Càrniques Celrà, S.L. and Grupo Empresarial Costa, S.L signed an investment and partnership agreement that gave rise to the incorporation of the company Glicopepton Biotech, S.L., whose share capital is currently held 51% by ROVI, while the other two partners hold 24.5% each.

About ROVI

ROVI is a pan-European pharmaceutical company specialising and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already marketed in 89 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe, and it is now marketed in 38 countries. ROVI continues to develop the ISM®

Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es.